Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3350-3357

  Heine, H S ^a   Bassett, J ^a   Miller, L ^a   Bassett, A ^a   Ivins, B E ^a   Lehoux, D ^b   Arhin, F F ^b   Parr Jr , T R ^b   Moeck, G ^b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Targanta Therapeutics   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; ORITAVANCIN;

AEROSOL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; BACTERIAL STRAIN; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG RESEARCH; EXPERIMENTAL INFECTION; INHALATION; LETHAL DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SINGLE DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ANIMALS; ANTHRAX; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; DISEASE MODELS, ANIMAL; GLYCOPEPTIDES; HUMANS; MICE; MICROBIAL SENSITIVITY TESTS; SPORES, BACTERIAL; TREATMENT OUTCOME;

EID: 50949120690     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00360-08     Document Type: Article

References (42)

1. Allen, N. E., and T. I. Nicas. 2003. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26:511-532.
2. Arhin, F. F., I. Sarmiento, A. Belley, G. A. McKay, D. C. Draghi, P. Grover, D. Sahm, T. R. Parr, Jr., and G. Moeck. 2008. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob. Agents Chemother. 52:1597-1603.
3. Arhin, F. F., I. Sarmiento, T. R. Parr, Jr., and G. Moeck. 2007. Mechanisms of action of oritavancin in Staphylococcus aureus, abstr. C1-1471, p. 85. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
4. Barcia-Macay, M., C. Seral, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50:841-851.
5. Boylan, C. J., K. Campanale, P. W. Iversen, D. L. Phillips, M. L. Zeckel, and T. R. Parr, Jr. 2003. Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 47:1700-1706.
6. Bradaric, N., and V. Punda-Polic. 1992. Cutaneous anthrax due to penicillin-resistant Bacillus anthracis transmitted by an insect bite. Lancet 340:306-307.
7. Brook, I., T. B. Elliott, H. I. Pryor II, T. E. Sautter, B. T. Gnade, J. H. Thakar, and G. B. Knudson. 2001. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int. J. Antimicrob. Agents 18:559-562.
8. Chen, Y., F. C. Tenover, and T. M. Koehler. 2004. β-Lactamase gene expression in a penicillin-resistant Bacillus anthracis strain. Antimicrob. Agents Chemother. 48:4873-4877.
9. Choe, C., S. Bouhaouala, I. Brook, T. Elliott, and G. Knudson. 2000. In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne. Antimicrob. Agents Chemother. 44:1766.
10. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - seventh edition. CLSI document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Deziel, M. R., H. Heine, A. Louie, M. Kao, W. R. Byrne, J. Basset, L. Miller, K. Bush, M. Kelly, and G. L. Drusano. 2005. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob. Agents Chemother. 49:5099-5106.
13. Doǧanay, M., and N. Aydin. 1991. Antimicrobial susceptibility of Bacillus anthracis. Scand. J. Infect. Dis. 23:333-335.
14. Federal Register. 2002. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed. Regist. 67:37988-37998.
15. Fetterly, G. J., C. M. Ong, S. M. Bhavnani, J. S. Loutit, S. B. Porter, L. G. Morello, P. G. Ambrose, and D. P. Nicolau. 2005. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob. Agents Chemother. 49:148-152.
16. Friedlander, A. M., S. L. Welkos, M. L. Pitt, J. W. Ezzell, P. L. Worsham, K. J. Rose, B. E. Ivins, J. R. Lowe, G. B. Howe, P. Mikesell, and W. B. Lawrence. 1993. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 167:1239-1242.
17. Gold, H. 1955. Anthrax: a report of one hundred seventeen cases. Arch. Intern. Med. 96:387-396.
18. Heine, H. S., C. M. Rubino, J. Bassett, L. Miller, P. G. Ambrose, S. M. Bhavnani, A. Forrest, G. L. Drusano, A. Beaudry, J. Li, N. Janjic, and S. C. Gill. 2007. Pharmacokinetic-pharmacodynamic (PK-PD) assessment of faropenem (FAR) in a lethal murine-Bacillus anthracis (BA) inhalation post-exposure prophylaxis model, abstr. A-1435, p. 34. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
19. Heine, H. S., J. Bassett, and L. Miller. 2005. In vitro and in vivo activity of dalbavancin (DAL) against Bacillus anthracis (BA), abstr. F-2079, p. 232. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
20. Heine, H. S., J. Bassett, L. Miller, A. Basset, T. R. Parr, Jr., and G. Moeck. 2007. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax, abstr. A-101, p. 23. Abstr. 107th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.
21. Heine, H. S., J. Bassett, L. Miller, G. P. Andrews, and W. R. Byrne. 2004. Efficacy of daptomycin against Bacillus anthracis (anthrax) in a murine model of anthrax-spore inhalation, abstr. A-051, p. 10-11. Abstr. 104th Gen. Meet. Am. Soc. Microbiol. American Society for Microbiology, Washington, DC.
22. Heine, H. S., J. Bassett, L. Miller, J. M. Hartings, B. E. Ivins, M. L. Pitt, D. Fritz, S. L. Norris, and W. R. Byrne. 2007. Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model. Antimicrob. Agents Chemother. 51:1373-1379.
23. Heine, H. S., R. Dicks, and G. Andrews. 2001. In vitro activity of oritavancin (LY333328), levofloxacin, meropenem, GAR936 and linezolid against strains of Bacillus anthracis, abstr. E-524, p. 173. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
24. Inglesby, T. V., T. O'Toole, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. M. Friedlander, J. Gerberding, J. Hauer, J. Hughes, J. McDade, M. T. Osterholm, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
25. Keim, P., L. B. Price, A. M. Klevytska, K. L. Smith, J. M. Schupp, R. Okinaka, P. J. Jackson, and M. E. Hugh-Jones. 2000. Multiple-locus variable-number tandem repeat analysis reveals genetic relationships within Bacillus anthracis. J. Bacteriol. 182:2928-2936.
26. Leffel, E. K., and L. M. Pitt. 2006. Anthrax, p. 77-93. In J. R. Swearengen (ed.), Biodefense. Research methodology and animal models. CRC Press Taylor and Francis, Boca Raton, FL.
27. Lehoux, D., F. F. Arhin, I. Fadhil, K. Laquerre, V. Ostiguy, I. Sarmiento, G. Moeck, and T. R. Parr, Jr. 2006. Oritavancin demonstrates rapid and sustained bactericidal activity in the rat granuloma pouch model of Staphylococcus aureus infection, abstr. B-404, p. 38. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
28. Lehoux, D., G. A. McKay, I. Fadhil, K. Laquerre, M. Malouin, V. Ostiguy, G. Moeck, and T. R. Parr, Jr. 2007. Efficacy of oritavancin in a mouse model of Streptococcus pneumoniae pneumonia, abstr. P-1781. Abstr. 17th Eur. Congr. Clin. Microbiol. Infect. Dis. and 25th Int. Congr. Chemother. European Society of Clinical Microbiologyand Infectious Diseases, Basel, Switzerland.
29. Leitenberg, M. 1993. The biological weapons program of the former Soviet Union. Biologicals 212:187-191.
30. Lightfoot, N. F., R. J. D. Scott, and P. C. B. Turnbull. 1990. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med. Bull. 68(Suppl.):95-98.
31. Loving, C. L., M. Kennett, G. M. Lee, V. K. Grippe, and T. J. Merkel. 2007. Murine aerosol challenge model of anthrax. Infect. Immun. 75:2689-2698.
32. Materon, I. C., M. Queenan, T. M. Koehler, K. Bush, and T. Palzkill. 2003. Biochemical characterization of β-lactamases Bla1 and Bla2 from Bacillus anthracis. Antimicrob. Agents Chemother. 47:2040-2042.
33. McKay, G. A., I. Fadhil, S. Beaulieu, S. Ciblat, A. Rafai Far, G. Moeck, and T. R. Parr, Jr. 2006. Oritavancin disrupts transmembrane potential and membrane integrity concomitantly with cell killing in Staphylococcus aureus and vancomycin-resistant enterococci, abstr. C1-682, p. 76. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
34. Meyerhoff, A., R. Albrecht, J. M. Meyer, P. Dionne, K. Higgins, and D. Murphy. 2004. US Food and Drug Administration approval of ciprofloxacin hydrochloride for management of postexposure inhalational anthrax. Clin. Infect. Dis. 39:303-308.
35. Nguyen, H. A., O. Denis, A. Vergison, P. M. Tulkens, M. Struelens, and F. Van Bambeke. 2007. Comparative intracellular activity of 10 antistaphylococcal antibiotics (AABS) against a stable small colony variant (SCV) of S. aureus in a model of human THP-1 macrophages, abstr. A-1437, p. 34. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
36. Pile, J. C., J. D. Malone, E. M. Eitzen, and A. M. Friedlander. 1998. Anthrax as a potential biological warfare agent. Arch. Intern. Med. 158:429-434.
37. Pollock, M. R. 1950. Penicillinase adaptation in B. cereus: adaptive enzyme formation in the absence of free substrate. Br. J. Exp. Pathol. 31:739-753.
38. Poulakou, G., and H. Giamarellou. 2008. Oritavancin: a new promising agent in the treatment of infections due to gram-positive pathogens. Expert Opin. Investig. Drugs 17:225-243.
39. Price, L. B., A. Volger, T. Pearson, J. D. Busch, J. M. Schupp, and P. Keim. 2003. In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob. Agents Chemother. 47:2362-2365.
40. Sivko, G., K. Gebhardt, P. Olson, R. Hunt, Z. Xu, P. Flavin, D. Eiznhamer, and M. Flavin. 2007. Efficacy of cethromycin against a lethal inhalation anthrax challenge in rhesus macaques, abstr. B-2031, p. 64-65. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
41. Van Bambeke, F., S. Carryn, C. Seral, H. Chanteux, D. Tyteca, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2004. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother. 48: 2853-2860.
42. Wang, T., S. Walker, and D. E. Kahne. 2007. Probing the mechanism of inhibition of bacterial peptidoglycan glycotransferases by glycopeptide analogs, abstr. C1-1474, p. 86. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.